Streptomycin is an antibiotic drug, the first of a class of drugs called aminoglycosides to be discovered, and was the first antibiotic remedy for tuberculosis. It is derived from the actinobacteriumStreptomyces griseus. Streptomycin stops bacterial growth by damaging cell membranes and inhibiting protein synthesis. Specifically, it binds to the 23S rRNA molecule of the bacterial ribosome, which prevents the release of the growing protein (polypeptide chain). Humans have structurally different ribosomes than bacteria, thereby allowing the selectivity of this antibiotic for bacteria. Streptomycin cannot be given orally, but must be administered by regular intramuscular injection.
The details and credit for the discovery of streptomycin were strongly contested by Albert Schatz and resulted in litigation. The contention arose because Schatz was the graduate student in charge of performing the lab work on streptomycin; however, it was argued that he was using techniques, equipment and lab space of Waksman's while under Waksman's direction. There is contention as to whether or not Schatz should have been included in the Nobel Prize awarded in 1952. However, the committee stated that the Nobel Prize was awarded not only for the discovery of streptomycin but also for the development of the methods and techniques that led up to its discovery and the discovery of many other antibiotics.
WL Issued to Amrex Zetron Inc FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Amrex Zetron Inc on 14 Apr 2009 by Los Angeles District Office WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Cote, Charles J., MD FDA Mon, 02 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Cote, Charles J., MD on 02 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Genzyme Corporation FDA Fri, 27 Feb 2009 00:00:00 -0400 FDA Warning Letter Issued to Genzyme Corporation on 27 Feb 2009 by New England District Office WL Issued to Hammill Manufacturing Company FDA Tue, 06 Jan 2009 00:00:00 -0400 FDA Warning Letter Issued to Hammill Manufacturing Company on 06 Jan 2009 by Cincinnati District Office
CFDA: FDA Latest Drug GCP Warning Letters
WL Issued to Coast Institutional Review Board FDA Tue, 14 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Coast Institutional Review Board on 14 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Branitz, Bruce, MD FDA Thu, 09 Apr 2009 00:00:00 -0400 FDA Warning Letter Issued to Branitz, Bruce, MD on 09 Apr 2009 by Center for Drug Evaluation and Research WL Issued to Bukowski, Ronald M, MD FDA Mon, 30 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Bukowski, Ronald M, MD on 30 Mar 2009 by Center for Drug Evaluation and Research WL Issued to Youabian, Inc FDA Tue, 17 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Youabian, Inc on 17 Mar 2009 by Los Angeles District Office WL Issued to Provena St. Joseph's Medical Center IRB FDA Thu, 12 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Provena St. Joseph's Medical Center IRB on 12 Mar 2009 by Center for Biologics Evaluation and Research WL Issued to Paulson, Daniel M., MD FDA Wed, 11 Mar 2009 00:00:00 -0400 FDA Warning Letter Issued to Paulson, Daniel M., MD on 11 Mar 2009 by Center for Drug Evaluation and Research